PTAB finds Sun Pharma’s patent '028 unpatentable, a win for Biofrontera in patent dispute

Biofrontera Inc.

PTAB issued Final Written Decision on Feb 23, 2026, invalidating all challenged claims of Sun's U.S. Patent No. 11,697,028.
Sun may request rehearing, petition the Director, or appeal to the Federal Circuit.
Decision does not affect the separate '512 patent; that IPR petition was denied on administrative grounds.
Impact on parallel District Court and ITC proceedings is not yet determinable.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.